GH

Guardant Health, Inc. (GH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has been named to Business Insider's America's Most Innovative Businesses 2027 list, earning the highest rating available with a five-star recognition awarded to only other 12 biotechnology research companies in the category. The inaugural Business Insider list recognizes companies for their innovative performance over the preceding five years, positioning Guardant am.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal. “We strongly disagree with this decision and will prompt.

A Delaware federal judge finalized a ruling ordering Guardant Health (NASDAQ:GH) to pay over $245.2 million to TwinStrand Biosciences and the University of Washington, cementing a November 2023 jury verdict that found Guardant willfully infringed on two Duplex Sequencing patents.

Guardant Health NASDAQ: GH highlighted growth across its oncology testing, minimal residual disease, and colorectal cancer screening businesses at the Canaccord Genuity Growth Conference, with co-CEOs Helmy Eltoukhy and AmirAli Talasaz pointing to expanding adoption, new reimbursement developments, and planned product launches.

Guardant Health, Inc. (GH) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

Guardant Health is experiencing robust growth, driven by its MRD and screening businesses. Recent FDA approvals, expanded reimbursement, and inclusion in clinical guidelines should help to ensure growth remains strong going forward. Competition in both screening and MRD monitoring is set to intensify in coming years, though.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on July 21, 2026, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 46,044 shares of its common stock to 149 new non-executive employees with a grant date of August 3, 2026, under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The RSUs.

Guardant Health, Inc. (GH) Q2 2026 Earnings Call Transcript

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. Canaccord Genuity 46th Annual Growth Conference in Boston, MA Fireside chat on Wednesday, August 12th at 3:00 p.m. Eastern Time Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY Fireside chat on Tuesday, September 15th at 7:45 a.m. Eastern Time Interested parties may access liv.